MedTrace Logo

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies

NCT00129337 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2011-03-01

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there. The effect of bavituximab on tumor responses will also be examined.

Conditions

Interventions

DRUG

Bavituximab

Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).

Sponsors & Collaborators

  • Peregrine Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Nuhad Ibrahim, MD · The University of Texas MD Anderson Cancer Center

  • Linda Garland, MD · University of Arizona

  • Lee Rosen, MD · Premiere Oncology, A Medical Corporation (Santa Monica)

  • Lucas Wong, MD · Scott & White Memorial Hospital

  • Lee S Schwartzberg, MD, FACP · The West Clinic

  • David E Gerber, MD · University of Texas Southwestern Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00129337 on ClinicalTrials.gov